Pliant Therapeutics | 8-K:重大事件
Pliant Therapeutics | 8-K:重大事件
Pliant Therapeutics | 10-Q:季度报表
Pliant Therapeutics | 8-K:Pliant Therapeutics提供公司最新情况并报告2024年第一季度财务业绩
Pliant Therapeutics | 4:持股变动声明-高管 Cummings Keith Lamont
Pliant Therapeutics | DEFA14A:其他
Pliant Therapeutics | DEF 14A:股东委托书决议
Pliant Therapeutics | 8-K:重大事件
Pliant Therapeutics | S-8:员工福利计划证券登记
Pliant Therapeutics | 10-K:年度报表
Pliant Therapeutics | 8-K:Pliant Therapeutics提供公司最新情况并报告2023年第四季度财务业绩
Pliant Therapeutics | SC 13G:超过5%持股股东披露文件-Blue Owl Capital Holdings LP(5.02%)
Pliant Therapeutics | SC 13G:超过5%持股股东披露文件-Mathew P. Arens(6.14%),F(6.07%)
Pliant Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Redmile Group, LLC(4.5%),Jeremy C. Green(4.5%)
Pliant Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Third Rock Ventures IV, L.P.(3.6%),Third Rock Ventures GP IV, L.P.(3.6%)等
Pliant Therapeutics | SC 13G:超过5%持股股东披露文件-T. ROWE PRICE ASSOCIATES, INC.(6.3%)
Pliant Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Deep Track Capital, LP(9.60%),Deep Track Biotechnology Master Fund, Ltd.(9.60%)等
Pliant Therapeutics | SC 13G:超过5%持股股东披露文件-The Vanguard Group(5.12%)
Pliant Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-FMR LLC(6.617%),Abigail P. Johnson(6.617%)
Pliant Therapeutics | SC 13G:超过5%持股股东披露文件-Laurion Capital Management LP(5.98%),Benjamin Alexander Smith(5.98%)等
暂无数据